Second generation liposomal cancer therapeutics: Transition from laboratory to clinic

Sen, Koushik; Mandal, Mahitosh

doi:10.1016/j.ijpharm.2013.03.006

Cited by 63 publications

(39 citation statements)

References 227 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…26,27 However, it has to be noted that although liposomal formulations reached from the laboratory to the clinic, the vast number of research papers is not commensurate with the rather limited number of the clinical 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 6 studies that were performed [28][29][30][31] and the number of available marketable products. Therefore, upgrading liposomal drug delivery properties is still required which can be achieved by proper lipid selection and molecular engineering of their external surface, for instance by the introduction of appropriate functional moieties.…”

Section: Introductionmentioning

confidence: 99%

Triphenylphosphonium Decorated Liposomes and Dendritic Polymers: Prospective Second Generation Drug Delivery Systems for Targeting Mitochondria

2016

View full text Add to dashboard Cite

Targeting specific intracellular organelles has been a biological process of significant interest. Specifically, for mitochondrial targeting, conventional liposomal and dendritic polymer nanoparticles were selected to be presented in this miniperspective. Both types of nanoparticles were decorated on their external surface with triphenylphosphonium cation (TPP), a well-known and effective mitochondrial targeting moiety. Due to their advantageous specificity toward mitochondria, these nanoparticles may be considered as prospective second generation drug delivery systems (DDSs). Functionalized liposomal and dendritic nanoparticles are conveniently prepared, and although they encounter several hurdles on their route from the extracellular environment to the interior of mitochondria, they manage to be accumulated inside them in experiments in vitro. Therefore, the TPP-functionalized nanoparticles presented in this miniperspective can prove effective DDSs and efforts should be continued to obtain results that will trigger further studies including clinical studies, hopefully leading to effective drugs for mitochondrial diseases. In fact, since these DDSs enter and act at the site where the dysfunction exists, a new medicine subspecialty is emerging, the so-called mitochondrial medicine.

show abstract

Section: Introductionmentioning

confidence: 99%

Triphenylphosphonium Decorated Liposomes and Dendritic Polymers: Prospective Second Generation Drug Delivery Systems for Targeting Mitochondria

2016

View full text Add to dashboard Cite

show abstract

“…[19][20][21][22] For example, several paclitaxel formulations have been developed and tested in clinical research. In China, paclitaxel liposomes (Lipusu ® ; Luye Pharma) are already marketed.…”

Section: Liposomes For the Delivery Of Chemotherapeuticsmentioning

confidence: 99%

“…19 The development of SPI-77 was stopped due to the lack of release of cisplatin from the liposomes. 24,25 In addition, the development of LiPlaCis ® , another liposomal cisplatin formulation, 19 Sen and Mandal, 20 and Slingerland et al 21 IV. NOVEL APPROACHES FOR CANCER THERAPIES was stopped after a Phase I study when it was found that LiPlaCis did not prevent the renal toxicity of cisplatin and the incidence of acute infusion reactions was relatively high in this trial.…”

Section: Liposomes For the Delivery Of Chemotherapeuticsmentioning

confidence: 99%

See 1 more Smart Citation

Recent Advances and Trends in the Brain Delivery of Small Molecule Based Cancer Therapies

Gladdines

Visser

Boer

et al. 2015

Novel Approaches and Strategies for Biologics, Vaccines and Cancer Therapies

View full text Add to dashboard Cite

“…At this point, non-viral gene delivery has been the subject of increasing attention due to its relative safety, simple use and easy handling compared to viral vectors 21,22 . Among lipid based non-viral vectors, liposomes are the most widely used carriers for in vitro and in vivo gene delivery 23 . Lipofectamine 2000 is a commercialized cationic liposome based reagent, which has been extensively used for in vitro gene delivery purposes due to its high transfection efficiency 24 .…”

Section: Introductionmentioning

confidence: 99%

New Insights into Gene Delivery to Human Neuronal Precursor NT2 Cells: A Comparative Study between Lipoplexes, Nioplexes, and Polyplexes

et al. 2015

View full text Add to dashboard Cite

The transfection of human NTera2/D1 teratocarcinoma-derived cell line (or NT2 cells) represents a promising strategy for the delivery of exogenous proteins or biological agents into the central nervous system (CNS). The development of suitable nonviral vectors with high transfection efficiencies requires a profound knowledge of the whole transfection process. In this work, we elaborated and characterized in terms of size and zeta potential three different nonviral vectors: lipoplexes (144 nm; -29.13 mV), nioplexes (142.5 nm; +35.4 mV), and polyplexes (294.8 nm; +15.1 mV). We compared the transfection efficiency, cellular uptake, and intracellular trafficking of the three vectors in NT2 cell line. Lipoplexes exhibited the highest percentages of EGFP positive cells. The values obtained with polyplexes were lower compared to lipoplexes but higher than the percentages obtained with nioplexes. Cellular uptake results had a clear correlation with respect to the corresponding transfection efficiencies. Regarding the endocytosis mechanism, lipoplexes enter in the cell, mainly, via clathrin-mediated endocytosis (CME) while polyplexes via caveolae-mediated endocytosis (CvME). Nioplexes were discarded for this experiment due to their low cellular uptake. By simulating an artificial endosome, we demonstrated that the vectors were able to release the DNA cargo once inside the late endosome. The data collected from this assay showed that at 6 h the genetic material carried by polyplexes was still located in the late endosome, while DNA carried by lipoplexes was already in the nucleus. This result indicates a faster intracellular traffic of the lipid-based vectors. Overall, our work gives new insights into the transfection process of NT2 cells by different nonviral vectors as a first step in the development of ex vivo gene therapy platform.

show abstract

Second generation liposomal cancer therapeutics: Transition from laboratory to clinic

Cited by 63 publications

References 227 publications

Triphenylphosphonium Decorated Liposomes and Dendritic Polymers: Prospective Second Generation Drug Delivery Systems for Targeting Mitochondria

Triphenylphosphonium Decorated Liposomes and Dendritic Polymers: Prospective Second Generation Drug Delivery Systems for Targeting Mitochondria

Recent Advances and Trends in the Brain Delivery of Small Molecule Based Cancer Therapies

New Insights into Gene Delivery to Human Neuronal Precursor NT2 Cells: A Comparative Study between Lipoplexes, Nioplexes, and Polyplexes

Contact Info

Product

Resources

About